Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503685
Status:
COMPLETED
Last Update Posted:
2018-06-06
First Post:
2007-07-17
Brief Title:
Study Using IMC-A12 Cixutumumab With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Phase 2 Clinical Trial of IMC-A12 as a Single Agent or in Combination With Cetuximab in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participants with metastatic Colorectal Cancer mCRC who have progressed on a prior Anti-epidermal growth factor receptor EGFR regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess response survival durations of response safety and tolerability as well as pharmacodynamics of IMC-A12 and cetuximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| I5A-IE-JAEL | OTHER | Eli Lilly and Company | None |
| CP02-0657 | OTHER | None | None |
| CP13-0605 | OTHER | None | None |